Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087
Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P146
Published Online: 2015-11-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chen, Robert
Armand, Phillippe
Fanale, Michelle A
Ribrag, Vincent
Zinzani, Pier Luigi
Ricart, Alejandro D
Thompson, Seth
Balakumaran, Arun
Molin, Daniel
Shipp, Margaret A
Moskowitz, Craig H
Article History
First Online: 4 November 2015